The Nasdaq OMX Group Inc., of New York, reported the semi-annual re-ranking of the Nasdaq Biotechnology Index, which will become effective prior to the market's open on May 20

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement

Company (Location) Product Description Indication Status Date Actavis Inc. (Parsippany, N.J.) Testosterone Gel 1.62%, a generic version of AbbVie Inc.'s AndroGel 1.62% Absence of endogenous testosterone Filed an abbreviated NDA with the FDA 4/2/13 Almirall SA (Barcelona, Spain) and Forest Laboratories Inc. (New York) Aclidinium bromide and formoterol fumarate A long-acting muscarinic beta2 agonist and a long-acting beta2 agonist Chronic obstructive pulmonary disorder Top-line Phase III data

Company (Location) Product Description Indication Status Date Pfizer Inc. (New York) Prevenar 13 Pneumococcal polysaccharide conjugate vaccine Infections Phase III data showed it met all primary and secondary objectives focused on immunogenicity, tolerability and safety in adults 18 to 49 4/30/13 Tetraphase Pharmaceuticals Inc. (Watertown, Mass.) Antibiotics Two next-generation antibiotic candidates Community-acquired multidrug-resistant infections Studies demonstrated efficacy 4/30/13 Trius

New York) BMS-791325 Used in a combination regimen with dactlatasvir and asunaprevir Hepatitis C virus genotype 1 Interim Phase II data demonstrated sustained virologic response of up to 94% 4/24/13 Gilead Sciences Inc. (Foster City, Calif.) GS-7977 Sofosbuvir Hepatitis C virus genotypes 2 and 3, and genotypes 1, 4, 5 or 6 In three randomized trials, the rate of sustained virologic response after 12 weeks ranged from 50% for treatment-experienced patients to 78% for patients who were unwilling

Adaptive Biotechnologies, of Seattle, entered a collaboration with Bristol-Myers Squibb Co., of New York, for the discovery of immunological biomarkers in oncology

If the option is exercised, New York-based Forest will make payments of up to $430 million, depending upon the achievement of development and commercial milestones, plus royalties, and will carry forward the development and commercialization of TRV027

Izun Pharmaceuticals Corp., of New York, expanded its ongoing Phase II trial assessing the effect of IZN-6N4, on oral mucositis (OM) to two additional medical centers, Memorial Sloan Kettering Cancer Center and Beth Israel Medical Center, a component of the Continuum Cancer Centers of New York

Lumena licensed LUM001 from Pfizer Inc., of New York, where the compound was studied as a potential cholesterol-lowering agent

Celsus Therapeutics plc, of New York, reported interim results from the first cohort of its Phase II trial of MRX-6, a non-steroidal, anti-inflammatory cream, for allergic contact dermatitis

Reached at his office in New York on Friday, Blech told BioWorld Today that his attorney, Andrew Levander, advised him not to comment on the charges...According to an affidavit filed in the Southern District Court of New York, Blech is accused of scheming to defraud Bear Sterns (which provided clearing services for securities transactions by D. Blech & Co.) and his company's customers

with Forest Laboratories Inc., of New York, that was approved by the FDA in August 2012 in the dual indications of CIC and IBS-C in adults

Adamas Pharmaceuticals Inc., of Emeryville, Calif., and Forest Laboratories Inc., of New York, partnered to develop a fixed-dose combination of Namenda XR (memantine) and donepezil (MDX 8704) for dementia of Alzheimer's in the U.S

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported positive topline results from AUGMENT COPD, the second six-month pivotal Phase III trial evaluating the efficacy and safety of investigational fixed-dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair (Genuairn outside the U.S.) inhaler

Bristol-Myers Squibb Co., of New York, and Pfizer Inc., also of New York, said results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, showing that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliqus (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with nonvalvular atrial fibrillation

Among the top deals this year includes a partnership between Roche AG and Chiasma Inc., of New York, that could generate a total of $595 million

TNI BioTech Inc., of New York, named Joseph M. Fortunak a strategic consultant

N30 also is remarkable for raising funding entirely from "New York-based private capital," including Deerfield Capital Management LLC and its founder, Arnold Snider